Journal article
PhRMA white paper on ADME pharmacogenomics
Journal of clinical pharmacology, Vol.48(7), pp.849-889
07/2008
Handle:
https://hdl.handle.net/2376/118085
PMID: 18524998
Abstract
Pharmacogenomic (PGx) research on the absorption, distribution, metabolism, and excretion (ADME) properties of drugs has begun to have impact for both drug development and utilization. To provide a cross-industry perspective on the utility of ADME PGx, the Pharmaceutical Research and Manufacturers of America (PhRMA) conducted a survey of major pharmaceutical companies on their PGx practices and applications during 2003-2005. This white paper summarizes and interprets the results of the survey, highlights the contributions and applications of PGx by industrial scientists as reflected by original research publications, and discusses changes in drug labels that improve drug utilization by inclusion of PGx information. In addition, the paper includes a brief review on the clinically relevant genetic variants of drug-metabolizing enzymes and transporters most relevant to the pharmaceutical industry.
Metrics
4 Record Views
Details
- Title
- PhRMA white paper on ADME pharmacogenomics
- Creators
- J Andrew Williams - Pfizer Global Research and Development, 10646 Science Center Drive (CB10), San Diego, CA 92121, USA. james.williams2@pfizer.comTommy AnderssonTommy B AnderssonRebecca BlanchardMartin Otto BehmNadine CohenTimi EdekiMonique FrancKathleen M HillgrenKeith J JohnsonDavid A KatzMark N MiltonBernard P MurrayJoseph W PolliDeb RicciLisa A ShipleySubrahmanyam VangalaSteven A Wrighton
- Publication Details
- Journal of clinical pharmacology, Vol.48(7), pp.849-889
- Academic Unit
- Environment, School of the (CAHNRS)
- Publisher
- England
- Identifiers
- 99900547845201842
- Language
- English
- Resource Type
- Journal article